ArticleTranslational cancer research2025
Multivesicular body subunit 12B (MVB12B) overexpression represses proliferation and migration in bladder urothelial carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder urothelial carcinoma (BLCA) is a prevalent malignancy with high recurrence rates and limited therapeutic options, necessitating the identification of novel biomarkers for precision medicine. This study investigates the expression and clinical significance of multivesicular body subunit 12B (MVB12B) in BLCA, aiming to evaluate its potential as a prognostic biomarker and therapeutic target. Methods: We systematically evaluated MVB12B expression across 33 cancer types from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets, and the expression of MVB12B in BLCA was verified using the GSE3167 dataset. Next, the expression of MVB12B in BLCA patients with different clinicopathologic features was analyzed. Then, survival analysis was conducted through the Encyclopedia of RNA Interactomes (ENCORI) database. The receiver operating characteristic (ROC) curves were conducted to assess the diagnostic values of MVB12B. Furthermore, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database was used to construct a protein-protein interaction (PPI) network, and gene set enrichment analysis (GSEA) was performed to explore potential pathways through which MVB12B might influence BLCA. Finally, immunohistochemistry, quantitative real-time polymerase chain reaction (qRT-PCR) and cellular experiments were used to investigate the role of MVB12B in BLCA. Results: Our study reported that MVB12B was significantly downregulated in 14 cancer types, particularly in BLCA, in which low expression correlated with advanced tumor stage (III & IV), histological grade (high), and worse overall survival in BLCA patients. PPI networks identified MVB12B's interactions with endosomal sorting complex required for transport (ESCRT) components, and GSEA revealed that MVB12B was significantly involved in keratinization and intermediate filament organization. Experimental validation in clinical samples and BLCA cell lines (T24, UM-UC-3) revealed that MVB12B expression was reduced in tumor tissues and BLCA cell lines. Functional assays demonstrated that MVB12B overexpression suppressed BLCA cell proliferation and migration Conclusions: MVB12B functions as a tumor-suppressive role in BLCA and is associated with good prognosis in BLCA patients. MVB12B can be used as a potential biomarker for prognosis and therapeutic of BLCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.